The stability of free {lhCG (human chorionic gonadotrophin) was assessed using a dual cx-fetoprotein and free /JhCG assay. A significant increase in free {lhCG concentration was observed in heparinized samples left un separated for 24 h or more, the mean increase in 21 samples being 10·2% after 24 h (P= < 0,001), increasing to 45.7% after 96 h. Similar results were also obtained in clotted samples. The effect of the increase in free /JhCG on the Down's risk estimate was calculated to assess the impact of delayed sample transport and separation. The Down's risk increased in all samples with increasing separation time, but this was most significant in two samples where, using a cut off of one in 250, the risk classification changed from low risk to high risk. These results suggest that delayed sample separation can have a significant effect on screening programmes using free /JhCG, particularly with respect to those patients whose risk classification is changed.
Since the development of the first biochemical screening test for Down's syndrome by Wald et ai.,1 similar screening procedures have become routine in many laboratories. However, there is still no consensus as to what is the best combination of markers. Recent publications (2--4) have suggested that measurement of the free {l sub-unit of human chorionic gonadotrophin ({lhCG) may detect a greater proportion of affected pregnancies than total hCG. On the other hand, other studies have shown that free /JhCG concentrations increase during prolonged sample transportation.>?
Potential instability of free phCG is of concern to this laboratory if we are to adopt it in our routine Down's syndrome screening, as a substantial number of samples are taken by a community midwife or general practitioner. These frequently take 24 h to reach the laboratory and, if taken on a Friday, significantly longer. Recently, a new dual-label assay for the simultaneous measurement of a-fetoprotein (AFP) and free /JhCG has been developed! using the Delfia system. The stability of free phCG and AFP have been studied using this Correspondence: Dr J Beaman. assay and the impact of the results on the Down's risk estimate assessed.
METHODS AND SAMPLE COLLECTION
Samples were collected from women attending Southmead hospital antenatal clinic who were between 16 and 18 weeks' gestation by ultrasound scan. Initially, 21 women were recruited but a further 70 were subsequently added for confirmation and clarification of results. All patients were having a blood sample taken for routine Down's syndrome screening and were asked to provide a second 10 mL sample. Blood was collected into a lithium heparin vacutainer (Becton Dickinson UK Ltd, Oxfordshire, UK) and immediately placed on ice.
On arrival in the laboratory the tubes were placed on a roller mixer for approximately 2 min, eight 0·6 mL aliquots of whole blood were then taken into polypropylene tubes. The remaining sample was separated and the plasma also aliquoted into polypropylene tubes. The first assay was carried out within 1 h of venepuncture. Aliquots of whole blood and plasma were stored at room temperature and 4 DC and subsequently assayed after 4,24,48 and FIGURE 1. The percentage increase in free /JhCG concentration in (.) whole blood at room temperature. (.) whole blood at 4 cC and (JJ;.) plasma at room temperature. The bars illustrate the between sample variability. showing the observed maximum and minimum per cent changes in whole blood at room temperature. temperature were both found to prevent the increase in free phCG concentration. After 96 h there was no significant change from the levels measured within one hour of venepuncture ( Fig: 1) .
To assess the potential effect of delayed sample separation and the consequent increase in free phCG concentration on the Down's risk estimate this was calculated for heparinized whole blood after 0, 24 and 96 h at ambient temperature. Using a Down's risk of one in 250 as the cut off above which a pregnancy is classified as high risk, in the baseline sample two patients would have had a high Down's risk. After 24 h this increased to three patients, and after 96 h four patients would be considered to be at high risk. Details of the changes in risk estimates in all 21 samples are shown in Table 1 (columns 1 and 2). The mean increase in Down's risk estimate after 24 h was 17%, -the largest increase being 65%.
The effect of long-term storage of samples on free phCG concentration was investigated by storing the 21 samples at -20 C C for 6 months. A mean decrease in free phCG concentration of 7·5% was observed (paired t test, P= < 0.001), with a range of 0-21%. This finding was 96 h. Aliquots of plasma were also stored at -20 c C and assayed after 6 months. At the time of this study both serum and lithium heparin samples were accepted by the laboratory for routine Down's screening. Studies had shown no difference in AFP and total hCG results between the two sample types, and roughly equal numbers of each were received. Lithium heparin samples were chosen for the main study as this allowed easy aliquoting of samples, but subsequently stability was assessed on 20 clotted samples left at room temperature.
Free phCG and AFP were assayed using the Delfia dual AFP-free phCG kit (Wallac Oy, Turku, Finland)," the kits are suitable for use with either lithium heparin plasma or serum samples. Inter-assay precision determined over 14 assays was 3·8% at 8 U/L, increasing to 4·7% at 38 U/L for free phCG and for AFP was 3% or less at three concentrations up to 54 KU/L. Down's risk estimates were calculated related to maternal age at term and risk at the time of screening, using locally derived medians. The algorithm used was that described by Reynolds and Penney? using the reference data of Spencer et al. 9 Ethical approval for this study was obtained from the Southmead Medical Research Ethics committee.
RESULTS
When whole blood was left unseparated at ambient temperature the free phCG concentration increased as shown in Fig. 1 , which shows the mean change in free PhCG concentration in 21 samples at each time point, expressed as a per cent change from the baseline sample. After 4 h the increase is not statistically significant (paired t test, P = 0,487). After 24 h the mean increase is 10·2% rising to 45·7% after 96 h (P= < 0·001 at 24 h and above). However, considerable between sample variation was observed; after 96 h the smallest increase in concentration was 16% and the greatest 97%. The maximum and minimum changes in concentration at each time point are indicated by the bars in Fig. 1 . In a similar study on 20 clotted samples left at room temperature the mean increase in free phCG was 11·2% after 24 hand 50·2% after 96 h. These results are not significantly different from the plasma samples, unpaired t test, P = O· 5 at 24 and 96 h.
Storage of heparinized whole blood at 4 CC or separation and storage of plasma at room subsequently confirmed on a further 50 samples, where aliquots of plasma were stored at both -20°C and -70°C for 6 months. After 6 months at -20°C there was a mean decrease in free phCG concentration of 3·5% (P> <0,001), range +7·2 to -26%, whereas the aliquots stored at -70°C showed no significant change in concentration.
An unexpected finding of this study was that the AFP concentration apparently also increased during sample storage (Fig. 2) . In heparinized whole blood left at ambient temperature the mean AFP concentration increased by 5% after 4 h (P=0'014), rising to 8% after 24 hand 19% after 96 h (P= <0·001 at 24 h and above). The maximum and minimum change at each time point are indicated by the bars in Fig. 2 . In contrast to free phCG, this increase in aFP concentration was diminished but not prevented by separation of blood and storage of plasma at either room temperature or 4°C. In plasma stored at 4°C the AFP concentration increased by 9% after 96 h (P=0·005). In the 20 clotted samples left at room temperature the mean increase in AFP was 6% after 24 hand 12% after 96 h (P= <0·001 at 24 and 96 h). However, this increase is significantly lower than in the plasma samples (unpaired t test,
DISCUSSION
Our results using the Delfia dual assay show that free phCG concentrations increase significantly in unseparated blood samples left at ambient temperature. This is consistent with previous studies using other methods.>? However, once samples had been separated free phCG concentrations were found to be stable for at least 96 h and similarly if whole blood was stored at 4°C then no significant increase in free phCG was observed over 96 h. In contrast to this, on long-term storage for 6 months at -20°C a small but statistically significant decrease in free phCG concentration was observed.
The results of this study have important implications for both the use of free phCG as a marker for Down's risk screening and the validity of retrospective studies using stored samples. If samples are not separated for 24 h or more then the observed increase in the free phCG concentration can cause a significant increase in the Down's risk estimate, as shown in Table 1 . Previous studies on the instability of free phCG have tended to look at the increase in median values and the effect on hypothetical patients with AFP and free phCG results close to the respective medians'? and possible effects on the false positive rate." These studies have not addressed the effect of the observed changes in free phCG concentration in terms of the very variable between sample stability or from the point of view of the individual patient. Sanken and Bahner? drew attention to the importance of free /JhCG instability on individual Down's risk calculations but did not go on to calculate Down's risks on their samples. This study shows that for the patients with high or very low 'zero time' Down's risks, the increase in free phCG concentration would not alter the subsequent action. However, there will be a number of patients who would be classified as low risk, but whose risk estimate in fact falls close to the cut off. If the mean increase in Down's risk of 17% after 24 h observed in the study patients was representative of the screened population this would suggest that on average any patient with a risk of one in 300 on a sample separated within 4 h could have a risk of one in 250 if separation was delayed for 24 h. That is if one in 250 is used as the cut off they would move from the negative to screen positive group. In an audit of the first 22816 patients screened in this laboratory using AFP and total hCG,14 1·2% of samples had a Down's risk which fell into the range one in 250 to one in 300. Thus if it is assumed that the distribution of risk estimates would be similar when using free phCG, then approximately 1·2% of patients who would be given a low Down's risk estimate if their sample was separated within 4 h, could conversely be given a high risk result if sample transport and separation was delayed for 24 h. This figure does not take into account the significant variability in sample stability and therefore if only a very crude estimate of the true figure. Spencer et a/. 6 reported similar changes in free phCG concentrations in whole blood left at room temperature to those observed in this study, but concluded that this is not significant in the screening setting, as this relies on comparison of samples with normal data, when both data sets have similar changes. However, we would conclude from our data that because between-sample stability is extremely variable this would only be true for free phCG if samples are separated ideally within 4 h and certainly within the same working day. Laboratories who offer free phCG as part of a screening test for Down's syndrome on samples with widely varying separation times are accepting results which may vary significantly depending on the day the sample was taken and the reliability of hospital transport or post. If obstetricians and Ann cu« Biochem 1996: 33 patients being counselled because of a high Down's risk estimate were aware that the risk may have been much lower had the sample arrived in the laboratory a day earlier then it is probable that their confidence in the test would be undermined.
Our results would also suggest that validity of data from retrospective studies is highly questionable. First, the samples involved were usually collected for neural tube defect screening and measurement of AFP, which is generally considered to be very stable, so that it is unlikely that any effort was made to minimize separation times. Secondly, the samples have been stored, often for many years, at -20°C, and at this temperature we observed a small but significant decrease in free phCG concentration even after 6 months. Hence, these studies have potentially been performed on samples subjected to variable increases in free phCG concentration prior to separation, followed by an unquantifiable decrease while stored at -20°C. This may explain the lower detection rates observed by Macri et al:" in a prospective study compared to retrospective studies. Therefore we conclude that valid assessment of detection rates and false positive rates for Down's screening programmes using free phCG must come from large prospective studies, very few of which have been published to date. I 1-13 Centres using free /JhCG should however pay close attention to separation time and make every effort to ensure the samples are separated the same day.
Other authors 2 • 4 , 11-13 have concluded that free phCG is the marker of choice for Down's screening. The experience of this laboratory does not support this conclusion: first, because of the lack of reproducibility of results caused by different sample transportation times; and secondly, these studies have indicated that the use of free phCG gives improved detection rates in patients screened early at 14 to 16 weeks although our results from 2 years' Down's screening using total hCG indicate that it is screening early rather than the use of free phCG which is important." The overall detection rate at a cut off of one in 300 was 63%, but in women screened at 15 and 16 weeks the detection rate was 80% compared to 33% in those screened at 17 to 20 weeks, (hypothesis test P = 0'008).
The observed increase in AFP concentration in this study was a surprising observation. The DELFIA AFP kit has been used in our laboratory for several years, initially for neural tube defect screening and since January 1992 for Down's screening and studies had shown no instability problems and no difference in results between plasma and serum samples. It is particularly difficult to explain the increase in AFP observed using the dual AFP free phCG assay as the anti-AFP antibodies used in this kit are said by the manufacturer to be the same as those employed in their AFP kit. The mechanism of the observed increase in AFP remains unexplained as does the difference between plasma and serum.
The AFP concentration carries much less weight in the Down's risk calculation than hCG and the observed changes in AFP did not result in a large decrease in the Down's risk estimates, even in plasma, where the largest increases were observed. In those patients whose risk classification was altered from low risk to high risk by an increase in free phCG concentration the increase in AFP concentration was not sufficient to reverse this (Table 1) .
